

UKRI CHAIR AND MRC EXECUTIVE CHAIR RECRUITMENT

ANNEX A - LEGAL BASIS OF THE APPOINTMENTS OF UKRI CHAIR AND MRC EXECUTIVE CHAIR

UK Research and Innovation (UKRI) will formally enter existence on 01 April 2018 and has its legal basis in the Higher Education and Research Act 2017. Appointments are made by the Secretary of State for Business, Energy and Industrial Strategy (BEIS) under section 2 of Schedule 9 of the Act. The relevant sections are reproduced below.

Membership of UKRI

- 2 (1) UKRI is to consist of the following members appointed by the Secretary of State—
- (a) a chair (“the chair”),
 - (b) the Chief Executive Officer (“the CEO”),
 - (c) the Chief Finance Officer (“the CFO”), and
 - (d) at least nine and not more than twelve other members.
- 2 (2) In this Schedule, references to the “members of UKRI” are to the members mentioned in sub-paragraph (1).
- 2 (3) The chair may not also be the CEO or the CFO.
- 2 (4) Before appointing the members mentioned in sub-paragraph (1)(b) to (d), the Secretary of State must consult the chair.
- 2 (5) The Secretary of State must, in appointing the members of UKRI, have regard to the desirability of the members (between them) having experience of—
- (a) research into science, technology, humanities and new ideas,
 - (b) the development and exploitation of science, technology, new ideas and advancements in humanities, and
 - (c) industrial, commercial and financial matters, the charitable sector and the practice of any profession.
- 2 (6) The Secretary of State must, in appointing the members of UKRI, have regard to the desirability of the members including at least one person with relevant experience in relation to at least one of Wales, Scotland and Northern Ireland.
- 2 (7) “Relevant experience” means experience of one or more of the following—
- (a) research into science, technology, humanities or new ideas;
 - (b) the development or exploitation of science, technology, new ideas or advancements in humanities;
 - (c) industrial, commercial or financial matters, the charitable sector or the practice of any profession.

Written evidence submitted by the Department for Business, Energy and Industrial Strategy (PMU0001)

Membership of the Councils

- 3 (1) Each Council is to consist of—
 - (a) an executive chair appointed by the Secretary of State (the “executive chair”), and
 - (b) at least five and not more than twelve other members (the “ordinary Council members”).
- 3 (2) In this Schedule, a reference to the “Council members” is to the executive chair and the ordinary Council members of each Council.
- 3 (3) The Secretary of State may appoint one of the ordinary Council members of each Council after consulting the chair of UKRI.
- 3 (4) The other ordinary Council members are to be appointed by UKRI after consulting the executive chair.
- 3 (5) A majority of the ordinary Council members of a Council must be persons who are neither members, nor employees, of UKRI.

Terms of appointment and tenure

- 4 A person holds and vacates office as a member of UKRI or as a Council member in accordance with the terms of his or her appointment.
- 5 (1) This paragraph applies to a person (a “Ministerial appointee”) appointed as—
 - (a) a member of UKRI,
 - (b) an executive chair, or
 - (c) an ordinary Council member where the appointment was made by the Secretary of State.
- 5 (2) The terms and conditions of a Ministerial appointee’s appointment are to be determined by the Secretary of State; but that is subject to the following provisions of this Schedule.
- 5 (3) A Ministerial appointee may resign from office as a member of UKRI, executive chair or an ordinary Council member by notifying the Secretary of State.
- 5 (4) The Secretary of State may remove a Ministerial appointee from office on any of the following grounds—
 - (a) absence from UKRI’s or the Council’s meetings, as the case may be, for a continuous period of more than six months without UKRI’s or the Council’s permission,
 - (b) inability or unfitness to carry out the functions of the office, or
 - (c) such other grounds as the Secretary of State considers appropriate.

Written evidence submitted by the Department for Business, Energy and Industrial Strategy (PMU0001)

- 6 (1) This paragraph applies to a person (an “UKRI appointee”) appointed as an ordinary Council member where the appointment was made by UKRI.
- 6 (2) The terms and conditions of an UKRI appointee’s appointment are to be determined by UKRI; but that is subject to the following provisions of this Schedule.
- 6 (3) An UKRI appointee may resign from office as an ordinary Council member by notifying UKRI.
- 6 (4) UKRI may remove an UKRI appointee from office on any of the following grounds—
 - (a) absence from the Council’s meetings for a continuous period of more than six months without the Council’s permission,
 - (b) inability or unfitness to carry out the functions of the office, or
 - (c) such other grounds as UKRI considers appropriate.

Remuneration etc

- 7 (1) UKRI must pay to members of UKRI and Council members such remuneration as the Secretary of State may determine.
- 7 (2) UKRI must pay, or make provision for paying, to or in respect of a person who is or has been a member of UKRI or a Council member, such sums as the Secretary of State may determine in respect of pension, allowances, expenses or gratuities.
- 7 (3) If, where a person ceases to be a member of UKRI or a Council member, the Secretary of State determines that he or she should be compensated because of special circumstances, UKRI must pay him or her compensation of such amount as the Secretary of State may determine.

Written evidence submitted by the Department for Business, Energy and Industrial Strategy (PMU0001)

ANNEX B1 - UKRI CHAIR

1. The Recruitment Process

The recruitment for UKRI Chair was a fair and open competition run by the Department in accordance with the Governance Code for Public Appointments published by the Cabinet Office. This is a part-time (one day a week approx) and non-executive appointment. The length of term is set at 4-5 years.

The interview panel comprised:

Alex Chisholm - Permanent Secretary, BEIS

Sir John Bell - Regius Professor of Medicine, University of Oxford

Lady Eliza Manningham-Buller – Chair, Wellcome Trust (served as the Senior Independent Panel Member)

After preparation of information packs, which include details of the role and person specifications and terms and conditions the post was advertised. The role was posted on the Cabinet Office Public Appointments website and through comms channels. The campaign closed for applications on 29 November 2017. There were seven applications received. Following consideration of the applications the panel held combined long listing and short listing meetings on 6 December 2017. There was one candidate selected for interview. Interviews were held on 15 December 2017 where one candidate was found appointable. A panel report was then submitted to the Minister for Universities and Science (Jo Johnson) who considered the advice. Following this Sir John Kingman was offered the role. The Minister consulted the Prime Minister who indicated that she was content.

2. Job Description and Person Specification

Job Description – The Role:

Key Duties/ Objectives for the UKRI Chair from the launch of UKRI in April 2018

1. Formulating UKRI strategy – Ensure coherent strategy develops across the organisation on cross-cutting research and innovation priorities.
2. Work with the CEO to advise the Secretary of State on strategic priorities, the case for investment into BEIS, and spending review allocations to the executive bodies.
3. Build vital relationships with various partners aimed at realising the potential of UKRI research and business to drive economically beneficial outcomes. In particular, engaging with the academic community, Government departments, Parliament and relevant all-party groups as well as other public, private and third sector partners including those outside of the UK to increase the relevance and economic impact of UKRI's research.

Written evidence submitted by the Department for Business, Energy and Industrial Strategy (PMU0001)

4. Ensuring the UKRI board takes proper account of guidance provided by the Minister of State for Universities, Science, Research and Innovation.
5. Ensuring that there is coordination and co-operation with the Office for Students, the devolved higher education funding bodies and other key partners.
6. Working with the Senior Independent Members of each Council to ensure that UKRI's Councils operate effectively and are able to discharge their remits within UKRI.

Specific responsibilities include:

7. Chair board meetings, typically [eight] times a year, in a way that facilitates the corporate pursuit of UKRI's objectives and gives due consideration to the interests of all stakeholders across academia and business.
8. Chair the Appointments Panel and provide advice to the Secretary of State on appointments to the UKRI board. Assessing the performance of the Chief Executive and Board Members.
9. Chair the Remuneration Committee, which determines Director-level pay policy and contracts, and corporate bonuses, as well as regular attendance at the Audit and Finance Committee and attendance at the Strategy Committee when required.

Person Specification

We are looking for an outstanding individual with a passion for and knowledge of research and innovation to become Chair of UKRI.

Applications are sought from candidates who are able to command the confidence of the relevant academic, business, higher education and policy communities, promote effective stakeholder engagement, guide and challenge the development of UKRI's organisational approach, ensure the organisation is realising the full benefits of reform, and drive increased value for money and impact from research and innovation investments.

It is expected that you would be able to demonstrate the following abilities and attributes:

1. Ability to Chair the Board of a substantial organisation and ability to develop and drive forward strategic direction;
2. Exercise judgement across a broad spectrum of policy and high-level management issues and deal with complex and difficult discussions with diplomacy and resolve;

Written evidence submitted by the Department for Business, Energy and Industrial Strategy (PMU0001)

3. Engage credibly with the breadth of UKRI stakeholders at senior level, including Ministers and senior officials within Government;
4. Show a good understanding of governance and other governing body management issues such as an understanding of compliance and probity as these relate to a publically-funded organisation;
5. First rate communication and interpersonal skills coupled with a strong intellect and negotiation and influencing capability across a range of stakeholders;
6. Promote and embed diversity and an inclusive culture appropriate for a dynamic, flexible and innovative body; and
7. Ability to provide constructive challenge to the UKRI Executive and to drive forward change in behaviour and practice across the organisation.

Declarations of Interests

Candidates are told that if they or a family member have any personal or business interest or potential conflict of interest with the activities of the Body they are applying to then they will be expected to declare this.

They are also required to uphold the standards of conduct established by the Committee of Standards in Public Life, also known as the Nolan Principles.

Sir John Kingman did not declare any interests. He noted that Legal and General (of which he is Chair) have minor investments in the energy sector, and that the National Gallery (of which he is a trustee) has received funding from the Arts and Humanities Research Council.

Written evidence submitted by the Department for Business, Energy and Industrial Strategy (PMU0001)

ANNEX B2 - UKRI CHAIR - CV OF THE CANDIDATE

SIR JOHN KINGMAN

Group Chairman, Legal & General plc (2016-)

Interim Chair, UK Research and Innovation (2016-).

Second Permanent Secretary, HM Treasury (2012-16); Acting Permanent Secretary (April-July 2016)

Global co-head, Financial Institutions Group, Rothschild (2010-12; senior adviser 2017-)

Chief Executive, UK Financial Investments (2008-9)

HM Treasury (1998-2008):

- Second Permanent Secretary (2007-8)
- Managing Director, Public Services & Growth (2006-7)
- Managing Director, Finance & Industry (Jan-Oct 2006)
- Director, Enterprise & Growth Unit (2003-5)
- Head of Productivity & Structural Reform (2000-2)
- Press Secretary to Chancellor of the Exchequer (1999-2000)

Group Chief Executive's office, BP (1997-98)

"Lex" columnist, Financial Times (1995-97)

Previous civil service career (1991-95)

- Principal Private Secretary to Secretary of State, Department of National Heritage (1994-95)
- Private Secretary to Financial Secretary to the Treasury (1993-94)

Board experience

- Trustee, National Gallery (2017-). Chair, Finance and Audit Committees
- Trustee, Royal Opera House (2014-). Member, Finance & Operations and Audit & Risk Committees
- Board director, European Investment Bank (2003-6)
- Non-executive director, Framestore CFC Ltd (2003-6)
- Member, HM Treasury board (2006-8; 2012-6)
- Member, Development Trust Board, St Martin-in-the-Fields (2006-9)

Other

- KCB, 2016 Birthday Honours
- Chair of judges, 2017 Wolfson Prize
- Member, Prime Minister's Council for Science and Technology (2016-)

Written evidence submitted by the Department for Business, Energy and Industrial Strategy (PMU0001)

- Visiting Fellow, Institute for Government (2009-10)
- Visiting Fellow, Institute of Political and Economic Governance, University of Manchester (2003-6)
- Member, Global Advisory Board, Centre for Corporate Reputation, and Visiting Fellow, Oxford University (2007-)

Education

- World Fellow, Yale University (2004)
- St John's College, Oxford (1987-90; Casberd Scholar; BA Modern History 1st class)
- Westminster School (1982-6; Queen's Scholar)

Written evidence submitted by the Department for Business, Energy and Industrial Strategy (PMU0001)

ANNEX C1 – MRC EXECUTIVE CHAIR

1. The Recruitment Process

The recruitment for the Executive Chair of MRC was a fair and open competition run in accordance with the Governance Code for Public Appointments published by the Cabinet Office. This is an executive appointment and the length of term is set at 3-5 years.

The interview panel comprised:

Jenny Dibden – Director: Science, Research and Innovation, BEIS

Sir Mark Walport – Chief Executive Designate, UKRI

Sir John Bell - Regius Professor of Medicine, University of Oxford (Independent Panel Member)

After preparation of information packs, which include details of the role and person specifications and terms and conditions the post was advertised. The role was advertised on the Cabinet Office Public Appointments website and publicised through comms channels. In addition, given the specialist nature of the role, the Department used external search agents, Saxton Bampfylde. The campaign closed for applications on 22 September 2017. There were 12 applications received. Following consideration of the applications the panel held combined long listing and short listing meetings on 28 September 2017. There were six candidates selected for interview. Interviews were held on 20 October 2017 where three candidates were found appointable. A panel report was then submitted to the Minister for Universities and Science (Jo Johnson) who considered the advice. Following this Professor Fiona Watt was offered the role. The Minister has consulted the Prime Minister who has indicated that she is content.

2. Job Description and Person Specification

Job Description – The Role:

The main responsibilities of the MRC Executive Chair will be to:

- Lead and manage the MRC and its staff in the successful delivery of its objectives, providing the inclusive leadership, and the vision to develop the quality, outputs and impacts of its research, skills and capital investment portfolio;
- Work with, and Chair, the MRC Council to lead and develop MRC's strategic approach to the funding of research, in relation to both directed and responsive-mode programmes, to the funding of postgraduate and skills training and its investment in major longer term capital projects; and to ensure that the UK develops its world class position in medical research, supported by the Council's 'Senior Independent Member';
- Actively engage and consult with the academic community, charities, government and industry to develop and catalyse new ideas and communicate the strategic

Written evidence submitted by the Department for Business, Energy and Industrial Strategy (PMU0001)

outputs. This will involve close engagement with stakeholders in the full range of industries interested in medical research, including the biopharmaceutical industry, diagnostics and medical devices, food and medical informatics companies;

- Be a core member of the UK Research and Innovation Executive Team, led by and accountable to the UK Research and Innovation CEO, to deliver best value from the overall science and innovation funding system and actively contribute to the development and implementation of the strategy of UK Research and Innovation;
- Act to ensure UK Research and Innovation provides a strong, unified voice for science, research and innovation in the UK and globally, both in facilitating the dialogue with government and partners on the world stage
- Work collaboratively across UK Research and Innovation Councils to foster interdisciplinary work and build on collective capabilities, providing support and challenge when required. This may include specific responsibility for the strategy and delivery of one or more cross cutting area on behalf of all the Councils.
- Maximise efficiency and ensure value for money from public investment;
- Represent and develop positive relationships between the MRC and its numerous and diverse stakeholders in government and public funding agencies, medical research charities, higher education institutions, academic and research communities, industry and the public at large and internationally;

Person Specification

The Department for Business, Energy and Industrial Strategy wishes to attract the highest calibre of candidates for this role. The successful candidate will be able to command confidence and represent the MRC at the highest level of and be able to demonstrate the following:

Skills, Experience and Standing

- A highly respected medical scientist of international standing with a proven track record;
- An inspirational communicator able to command confidence and have credibility across both the academic domain of medical research and the broader stakeholder landscape;

Strategic Vision

- An ability to develop, lead and manage a clear and strategic vision for medical research through the development of high quality, value for money programmes built on a thorough understanding of and engagement with the stakeholder landscape.
- An ability to take a broad view of the MRC's objectives and issues arising across the range of medical research sciences;
- An ability to advise on major business developments which bring a significant change in the Council's role or activities and on its exposure to and management of risk;

Written evidence submitted by the Department for Business, Energy and Industrial Strategy (PMU0001)

Leadership and Management

- Proven leadership and management skills with a deep understanding and experience of change management and evidence of having successfully led cultural change and organisational development;
- Experience of managing and building capability of a cadre of skilled employees and programme managers and able to inspire and motivate colleagues at all levels in the organisation;

Breadth of Understanding

- In depth understanding of current developments in the full spectrum of the medical research landscape and other areas relevant to the work of the MRC; and
- An ability to understand and demonstrate the highest standards of medical research and its wider relevance to and impact on the cultural, social and economic wellbeing of the country.

Declarations of Interests

Candidates are told that if they or a family member have any personal or business interest or potential conflict of interest with the activities of the Body they are applying to then they will be expected to declare this.

They are also required to uphold the standards of conduct established by the Committee of Standards in Public Life, also known as the Nolan Principles.

Professor Fiona Watt declared that she serves on a number of committees and scientific advisory boards in the UK and internationally. She currently consults for two Biotech companies (Frequency Therapeutics Inc and OxStem) and is a member of the Unilever Scientific Advisory Board. She is also a non-executive director of the Cell and Gene Therapy Catapult. Some or all of these activities could be construed as potential conflicts of interest and she has undertaken to resign from the roles as appropriate, if appointed. In terms of her personal circumstances, she is married to Jim Smith, who is currently Director of Science at the Wellcome Trust.

Written evidence submitted by the Department for Business, Energy and
Industrial Strategy (PMU0001)

ANNEX C2 – MRC EXECUTIVE CHAIR - CV OF THE CANDIDATE

NAME: Fiona Mary WATT

QUALIFICATIONS AND RESEARCH EXPERIENCE

1973 - 1976	Cambridge University - 1st Class Honours B.A. in Natural Sciences (M.A. 1979)
1976 - 1979	Sir William Dunn School of Pathology University of Oxford - D.Phil.
1979 - 1981	Postdoctoral Associate, Department of Biology, M.I.T., Cambridge, Massachusetts, U.S.A.
1981 - 1986	Head of Molecular Cell Biology Laboratory, Kennedy Institute of Rheumatology, London.
1987 - 2006	Head of Keratinocyte Laboratory, CR-UK London Research Institute (formerly Imperial Cancer Research Fund)
2007 - 2012	Deputy Director, Cambridge CR-UK Institute; Herchel Smith Professor of Molecular Genetics, Cambridge University; Fellow of St John's College
2012 -	Director, Centre for Stem Cells and Regenerative Medicine

AWARDS AND HONOURS (selected)

Biological Council Medal, 1990
Member, European Molecular Biology Organization, 1999
President, British Society for Cell Biology, 1999-2006
Fellow, Academy of Medical Sciences, 2000
Fellow, Royal Society, 2003
President, International Society for Stem Cell Research (ISSCR), 2008
Honorary Foreign Member, American Academy of Arts and Sciences, 2008
American Society for Cell Biology (ASCB) Women in Cell Biology Senior Award,
2008
Member, Academia Europaea, 2009
MRC Suffrage Science Heirloom, 2011
King's College London award for public engagement, 2013
Hunterian Society Medal, 2015
Doctor Honoris Causa, Universidad Autonoma de Madrid, 2016
FEBS/EMBO Women in Science Award, 2016
Vice President (non-clinical), Academy of Medical Sciences, 2018
Honorary Member, Society for Investigative Dermatology, 2018

Written evidence submitted by the Department for Business, Energy and
Industrial Strategy (PMU0001)

COMMITTEE MEMBERSHIP (selected)

Medical Research Council (MRC) Molecular and Cellular Medicine Board Grants
Committee A, 1995-1997
Cancer Research Campaign Scientific Committee, 1998-2002
Cancer studies sub-panel member, UK Government Research Assessment
Exercise, 2001
MRC Molecular and Cellular Medicine Board, 2000-2005
Cancer Research UK Programmes Committee, 2002-2006
Royal Society working group on stem cells and cloning, 2003
Panel member, Pattison Report on UK stem cell initiative, 2005
Scientific Advisory Board, Canadian Stem Cell Network, 2006-
Scientific Advisory Board, Institute for Integrated Cell-Material Sciences (iCeMS),
Kyoto University, 2008-
Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA)
Scientific Advisory Board, 2008-
Wellcome Trust Investigator Awards, expert review group, Cell and Developmental
Biology, 2011- 2014
Member, Steering Committee for the UK Stem Cell Bank, 2011 - 2016
Scientific Advisory Board, Ontario-wide Stem Cell initiative and Centre for
Commercialization in Regenerative Medicine, 2011-
Specialist adviser, House of Lords Science and Technology Committee inquiry into
Regenerative Medicine, 2012
Jury member, New York Stem Cell Foundation-Robertson Stem Cell Investigator
Awards Program, 2013 – 2017
Advisory Board, bioRxiv preprint server, 2013-
Scientific Advisory Board, California Institute for Regenerative Medicine (CIRM),
2013
Scientific Advisory Board (SAB) of the Mechanobiology Institute, Singapore (MBI),
2014-
Scientific Advisory Committee, National Institute for Biological Standards and Control
(NIBSC), 2014-2017
Chair, Early Career Selection Committee, Wellcome Trust/DBT India Alliance, 2015
–
Member, Wellcome Trust Interview Panel, 2015 –
Member, European Molecular Biology Laboratory Scientific Advisory Committee,
2016-2018
Scientific Advisory Board, Biozentrum, University of Basel, 2016-2018
Evaluation panel, European Research Council (ERC) advanced grants, LS3 Cellular
and Developmental Biology, 2016
Member, Howard Hughes Medical Institute Medical Advisory Board, 2018-

SCIENTIFIC JOURNALS (selected)

Editor-in-Chief, Journal of Cell Science, 1992 - 2011
Associate Editor, Journal of Investigative Dermatology, 1990-1998 and 2002- 2007
Editorial Board, Current Opinion in Cell Biology, 1994-
Board of Reviewing Editors, Science, 2004–2005
Editorial Board, Cell Stem Cell, 2006-
Deputy Editor, eLife, 2011-

Written evidence submitted by the Department for Business, Energy and Industrial Strategy (PMU0001)

RECENT PUBLIC ENGAGEMENT (selected)

March 2012: 'Women in Science: Nurturing Nobels', discussion evening, Dana Centre, Science Museum, London; January 2013: interview with Times Higher Education on optimal laboratory size; May 2013: speaker, 'A Pint of Science' festival (<http://www.pintofscience.com>); inaugural Rosalind Franklin lecture, Hay Festival; interviews for BBC Radio 5 Live and the Today programme on stem cell therapy for stroke victims; July 2013: interview for "The Naked Scientists" on 'eLife, a revolution in publishing'; February 2014 public lecture at the Royal Society on stem cell research; May 2014: interview for BBC World News on eczema and cancer; November 2015, judge, Hall of FameLab, London; November 2017 BBC Radio 4 'Inside Science' interview on combined cell and gene therapy for skin disease.

TEACHING EXPERIENCE (selected)

1984-present	35 non-clinical PhDs, 12 clinical PhDs and 6 Masters students supervised to completion
1985-present	Laboratory placements for undergraduates and interns
1986-present	Lectures to BSc and MSc students, various Universities
1987-present	External examiner of 44 Ph.D., 1 MSc and 1 habilitation thesis
2016-present	Established and run Wellcome Trust 4 year PhD programme

CURRENT GRANT SUPPORT (selected)

PI, UK Regenerative Medicine Platform Immunomodulation Hub, 'Overcoming immunological barriers to regenerative medicine' (MR/LO22699/1), 2014-2018
Partner, EU Horizon2020 coordination and support action, EuroStemCell 'European Consortium for Communicating Stem Cell Research', 2014-2018
PI, BBSRC grant 'Effect of the topography of the human epidermal-dermal junction in influencing stem cell behaviour' (BB/M007219/1), 2015-2018
Director, Wellcome Trust PhD programme 'Cell therapies and regenerative medicine' (108874/Z/15/Z), 2016-2019
Partner, EU H2020 Twinning Network 'Gene2Skin', 2016-2018
PI, Cancer Research UK programme grant 'An integrated analysis of oral squamous cell carcinoma development and progression' (C219/A23522), 2017-2022
Theme lead, Regenerative Medicine and Cellular Therapy, Guy's and St Thomas' NHS Foundation Trust NIHR Biomedical Research Centre (IS-BRC-1215-20006), 2017-2022
PI, MRC programme grant 'Understanding the roles of distinct fibroblast subpopulations in skin homeostasis and disease' (MR/PO18823/1), 2017-2022
Co-PI, Danish National Research Foundation Center for Cellular Signal Patterns (CellPAT), 2017-2022
Wellcome Trust Senior Investigator Award 'Dynamic transition states in mammalian epidermis' (206439/Z/17/Z), 2018-2023
PI, Chan Zuckerberg Initiative pilot project for a Human Cell Atlas (skin) 'Optimised isolation and visualization of human skin cells', 2017-2018

PUBLICATIONS

Thesis

Watt, F.M. (1979)

Microtubule-organising centres in cells in culture and in hybrids derived from them.

D.Phil. Thesis, University of Oxford

Research Articles

248 primary research articles, including:

1. **Watt, F.M.** and Green, H. (1982) Stratification and terminal differentiation of cultured epidermal cells. *Nature* 295:434-436. PMID: 6895777.

2. Jones, P.H. and **Watt, F.M.** (1993) Separation of human epidermal stem cells from transit amplifying cells on the basis of differences in integrin function and expression. *Cell* 73:713-724. PMID: 8500165.

3. Jones, P.H., Harper, S. and **Watt, F.M.** (1995) Stem cell patterning and fate in human epidermis. *Cell* 80:83-93. PMID: 7813021.

4. Lowell, S., Jones, P., Le Roux, I., Dunne, J. and **Watt, F.M.** (2000) Stimulation of human epidermal differentiation by Delta-Notch signalling at the boundaries of stem-cell clusters. *Curr. Biol.* 10:491-500. PMID: 10801437.

5. Braun, K.M., Niemann, C., Jensen, U.B., Sundberg, J.P., Silva-Vargas, V. and **Watt, F.M.** (2003) Manipulation of stem cell proliferation and lineage commitment: visualisation of label-retaining cells in whole mounts of mouse epidermis. *Development* 130:5241-5255. PMID: 12954714.

6. Silva-Vargas, V., Lo Celso, C., Giangreco, A., Ofstad, T., Prowse, D.M., Braun, K.M. and **Watt, F.M.** (2005) β -catenin and Hedgehog signal strength can specify number and location of hair follicles in adult epidermis without recruitment of bulge stem cells. *Dev. Cell* 9:121-131. PMID: 15992546.

7. Jensen, K.B., Collins, C.A., Nascimento, E., Tan, D.W., Frye, M., Itami, S. and **Watt, F.M.** (2009) Lrig1 expression defines a distinct multipotent stem cell population in mammalian epidermis. *Cell Stem Cell* 4:427-439. PMID: 19427292.

8. Connelly, J.T., Gautrot, J.E., Trappmann, B., Tan, D.W.-M., Donati, G., Huck, W.T.S. and **Watt, F.M.** (2010) Actin and serum response factor transduce physical cues from the microenvironment to regulate epidermal stem cell fate decisions. *Nat. Cell Biol.* 12:711-718. PMID: 20581838.

9. Fujiwara, H., Ferreira, M., Donati, G., Marciano, D.K., Linton, J.M., Sato, Y., Hartner, A., Sekiguchi, K., Reichardt, L.F. and **Watt, F.M.** (2011) The basement

Written evidence submitted by the Department for Business, Energy and
Industrial Strategy (PMU0001)

membrane of hair follicle stem cells is a muscle cell niche. *Cell* 144:577- 589. PMID: 21335239.

10. Mulder, K.W., Wang, X., Escriu, C., Ito, Y., Schwarz, R.F., Gillis, J., Sirokmány, G., Donati, G., Uribe-Lewis, S., Pavlidis, P., Murrell, A., Markowetz, F. and **Watt, F.M.** (2012) Diverse epigenetic strategies interact to control epidermal differentiation. *Nature Cell Biol* 14:753-763. PMID: 22729083.

11. Trappmann, B., Gautrot, J.E., Connelly, J.T., Strange, D.G.T., Li, Y., Oyen, M.L., Cohen Stuart, M.A., Boehm, H., Li, B., Vogel, V., Spatz, J.P., **Watt, F.M.*** and Huck, W.T.S.* (*co-corresponding) (2012) Extracellular-matrix tethering regulates stem-cell fate. *Nature Materials* 11:642-649. PMID: 22635042.

12. Tan, D.W.M., Jensen, K.B., Trotter, M.W., Connelly, J.T., Broad, S. and **Watt, F.M.** (2013) Single-cell gene expression profiling reveals functional heterogeneity of undifferentiated human epidermal cells. *Development* 140:1433-1444. PMID: 23482486.

13. Gomez, C., Chua, W., Miremadi, A., Quist, S., Headon, D.J., and **Watt, F.M.** (2013) The interfollicular epidermis of adult mouse tail comprises two distinct cell lineages that are differentially regulated by Wnt, Edaradd and Lrig1. *Stem Cell Reports* 1:19-27. PMID: 24052938.

14. Driskell, R.R., Lichtenberger B.M., Hoste E., Kretzschmar, K., Simons, B.D., Charalambous, M., Ferron, S.R., Herauld, Y., Pavlovic, G., Ferguson-Smith, A.C. and **Watt, F.M.** (2013) Distinct fibroblast lineages determine dermal architecture in skin development and repair. *Nature* 504:277–281. PMID: 24336287.

15. Liakath-Ali, K., Vancollie, V.E., Heath, E., Smedley, D.P., Estabel, J., Sunter, D., DiTommaso, T., White, J.K., Ramirez-Solis, R., Smyth, I., Steel, K.P. and Watt, F.M. (2014) Novel skin phenotypes revealed by a genome-wide mouse reverse genetic screen. *Nature Comm* 5:3540. PMID: 24721909.

16. Viswanathan, P., Guvendiren, M., Chua, W., Telerman, S.B., Liakath-Ali, K., Burdick, J.A. and **Watt, F.M.** (2016) Mimicking the topography of the epidermal-dermal interface with elastomer substrates. *Integrative Biology* 8:21–29. PMID: 26658424

17. Kretzschmar, K., Weber, C., Driskell, R.R., Calonje, E., and **Watt, F.M.** (2016) Compartmentalized epidermal activation of β -catenin differentially affects lineage reprogramming and underlies tumour heterogeneity. *Cell Reports* 4:269-281. PMID: 26771241.

18. Lichtenberger, B.M., Mastrogiannaki M., and **Watt F.M.** (2016) Epidermal β -catenin activation remodels the dermis via paracrine signalling to distinct fibroblast lineages. *Nature Comm* 7:10537. PMID: 26837596.

19. Donati, G., Rognoni, E., Hiratsuka, T., Liakath-Ali, K., Hoste, E., Kar, G., Kayikci, M., Russel, R., Kretzschmar, K., Mulder, K., Teichmann, S. and **Watt, F.M.** (2017)

Written evidence submitted by the Department for Business, Energy and Industrial Strategy (PMU0001)

Wounding induces dedifferentiation of Gata6+ cells and acquisition of stem cell properties. *Nature Cell Biol.* 19:603-613. doi: 10.1038/ncb3532. PMID: 28504705.

20. Kilpinen, H., Goncalves, A., Leha, A., Afzal, V., Alasoo, K., Ashford, S., Bala, S., Bensaddek, D., Casale, F.P., Culley, O.J., Danecek, P., Faulconbridge, A., Harrison, P.W., Kathuria, A., McCarthy, D., McCarthy, S.A., Meleckyte, R., Memari, Y., Moens, N., Soares, F., Mann, A., Streeter, I., Agu, C.A., Alderton, A., Nelson, R., Harper, S., Patel, M., White, A., Patel, S.R., Clarke, L., Halai, R., Kirton, C.M., Kolb-Kokocinski, A., Beales, P., Birney, E., Danovi, D., Lamond, A.I., Ouwehand, W.H., Vallier, L., **Watt, F.M.***, Durbin, R.*, Stegle, O.*, Gaffney, D.J*. (*co-corresponding) (2017) Common genetic variation drives molecular heterogeneity in human iPSCs. *Nature.* 546:370-375. PMID: 28489815.

Reviews and Editorials

101 total, including:

Watt, F.M. and Hogan, B.L.M. (2000)
Out of Eden: stem cells and their niches.
Science 287:1427-1430.

Janes, S. M. and **Watt, F.M.** (2006)
New roles for integrins in squamous-cell carcinoma.
Nat. Rev. Cancer 6:175-183.

Arwert, E.N., Hoste, E. and **Watt, F.M.** (2012)
Epithelial stem cells, wound healing and cancer.
Nat. Rev. Cancer 12:170-180.

Lane, S.W., Williams, D.A. and **Watt, F.M.** (2014)
Modulating the stem cell niche for tissue regeneration.
Nat Biotechnol. 32:795-803. doi: 10.1038/nbt.2978

Watt, F.M. (2014)
Mammalian skin cell biology: at the interface between laboratory and clinic.
Science 346:937-940.

Smith, K.A., Arlotta, P., **Watt, F.M.** and Solomon S.L. (2015)
Seven actionable strategies for advancing women in science, engineering, and medicine.
Cell Stem Cell 16:221-224.

Weissman, I.L. and **Watt, F.M.** (2016)
CIRM and UKRMP: different ways to invest in regenerative medicine
Cell Stem Cell 19:19–22. PMID: 27392224

Lynch, M.D. and **Watt, F.M.** (2018)
Fibroblast heterogeneity: implications for human disease.

Written evidence submitted by the Department for Business, Energy and
Industrial Strategy (PMU0001)

J. Clin. Invest. 128: 26-35. doi: 10.1172/JCI93555

Webinars and movies (selected)

Stem Cell Research: From Utopian Dream to Reality (2016)

https://www.youtube.com/watch?v=JlqULf7xJ90&feature=em-subscriptions_digest

Advice on applying for an Early Career Fellowship from the Wellcome
Trust/India DBT Alliance:

<https://www.youtube.com/watch?v=2ZpX5EkGVqc&feature=youtu.be>